Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis

Biochemical Pharmacology

Volumn 77, Issue 8, 2009, Pages 1410-1417

  Fotoohi, Alan Kambiz ^a   Assaraf, Yehuda G ^b   Moshfegh, Ali ^a   Hashemi, Jamileh ^c   Jansen, Gerrit ^d   Peters, Godefridus J ^d   Larsson, Catharina ^c   Albertioni, Freidoun ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

7 Hydroxymethotrexate; Folylpolyglutamate synthetase; Leukemia; Methotrexate; Microarray; Real time quantitative RT PCR; Reduced folate carrier; Resistance; Thymidylate synthase

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); 7 HYDROXYMETHOTREXATE; ADENOSINE DEAMINASE; BREAST CANCER RESISTANCE PROTEIN; CYSTATHIONINE BETA SYNTHASE; FOLIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; MESSENGER RNA; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; REDUCED FOLATE CARRIER;

ABCG2 GENE; ADA GENE; ARTICLE; CBS GENE; CELL LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSPORT; ENZYME ACTIVITY; FPGS GENE; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MRP1 GENE; MTHFR GENE; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; T CELL LEUKEMIA; TRANSCRIPTION REGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CHILD; DRUG RESISTANCE, NEOPLASM; FOLIC ACID; GENE EXPRESSION PROFILING; HUMANS; METHOTREXATE; NUCLEOTIDES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES;

EID: 62549105273     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.12.026     Document Type: Article

References (31)

1. Assaraf Y.G. Molecular basis of antifolate resistance. Cancer Metastasis Rev 26 (2007) 153-181
2. Fotoohi A.K., and Albertioni F. Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leuk Lymphoma 49 (2008) 410-426
3. Gorlick R., Goker E., Trippett T., Waltham M., Banerjee D., and Bertino J.R. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 335 (1996) 1041-1048
4. Shafran A., Ifergan I., Bram E., Jansen G., Kathmann I., Peters G.J., et al. ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates. Cancer Res 65 (2005) 8414-8422
5. Volk E.L., and Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 63 (2003) 5538-5543
6. Gifford A.J., Kavallaris M., Madafiglio J., Matherly L.H., Stewart B.W., Haber M., et al. P-glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in methotrexate accumulation due to a point mutation in the reduced folate carrier gene. Int J Cancer 78 (1998) 176-181
7. Newton P.A., and Blakley R.L. 7-Hydroxymethotrexate formation in a human lymphoblastic cell line. Biochem Biophys Res Commun 122 (1984) 1212-1217
8. Farquhar D., and Loo T.L. Synthesis and biologic evaluation of 7-hydroxymethotrexate, 7-methylaminopterin, and 7-methylmethotrexate. J Med Chem 15 (1972) 567-569
9. Drake J.C., Allegra C.J., Baram J., Kaufman B.T., and Chabner B.A. Effects on dihydrofolate reductase of methotrexate metabolites and intracellular folates formed following methotrexate exposure of human breast cancer cells. Biochem Pharmacol 36 (1987) 2416-2418
10. Sholar P.W., Baram J., Seither R., and Allegra C.J. Inhibition of folate-dependent enzymes by 7-OH-methotrexate. Biochem Pharmacol 37 (1988) 3531-3534
11. Fotoohi K., Jansen G., Assaraf Y.G., Rothem L., Stark M., Kathmann I., et al. Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: implications for efficacy of methotrexate therapy. Blood 104 (2004) 4194-4201
12. Rask C., Albertioni F., Bentzen S.M., Schroeder H., and Peterson C. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia-a logistic regression analysis. Acta Oncol 37 (1998) 277-284
13. Albertioni F., Pettersson B., Beck O., Rask C., Seideman P., and Peterson C. Simultaneous quantitation of methotrexate and its two main metabolites in biological fluids by a novel solid-phase extraction procedure using high-performance liquid chromatography. J Chromatogr B Biomed Appl 665 (1995) 163-170
14. Jonsson G., Staaf J., Olsson E., Heidenblad M., Vallon-Christersson J., Osoegawa K., et al. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 46 (2007) 543-558
15. Saal L.H., Troein C., Vallon-Christersson J., Gruvberger S., Borg A., and Peterson C. BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biol 3 (2002) SOFTWARE0003
16. Yang M.C., Ruan Q.G., Yang J.J., Eckenrode S., Wu S., McIndoe R.A., et al. A statistical method for flagging weak spots improves normalization and ratio estimates in microarrays. Physiol Genom 7 (2001) 45-53
17. Autio R., Hautaniemi S., Kauraniemi P., Yli-Harja O., Astola J., Wolf M., et al. CGH-Plotter: MATLAB toolbox for CGH-data analysis. Bioinformatics 19 (2003) 1714-1715
18. Jansen G., Mauritz R., Drori S., Sprecher H., Kathmann I., Bunni M., et al. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 273 (1998) 30189-30198
19. Rothem L., Aronheim A., and Assaraf Y.G. Alterations in the expression of transcription factors and the reduced folate carrier as a novel mechanism of antifolate resistance in human leukemia cells. J Biol Chem 278 (2003) 8935-8941
20. Rothem L., Ifergan I., Kaufman Y., Priest D.G., Jansen G., and Assaraf Y.G. Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines. Biochem J 367 (2002) 741-750
21. Rothem L., Stark M., Kaufman Y., Mayo L., and Assaraf Y.G. Reduced folate carrier gene silencing in multiple antifolate-resistant tumor cell lines is due to a simultaneous loss of function of multiple transcription factors but not promoter methylation. J Biol Chem 279 (2004) 374-384
22. Ifergan I., Jansen G., and Assaraf Y.G. Cytoplasmic confinement of breast cancer resistance protein (BCRP/ABCG2) as a novel mechanism of adaptation to short-term folate deprivation. Mol Pharmacol 67 (2005) 1349-1359
23. Ifergan I., Shafran A., Jansen G., Hooijberg J.H., Scheffer G.L., and Assaraf Y.G. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J Biol Chem 279 (2004) 25527-25534
24. Kager L., Cheok M., Yang W., Zaza G., Cheng Q., Panetta J.C., et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 115 (2005) 110-117
25. Assaraf Y.G. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Update 9 (2006) 227-246
26. Chen Z.S., Lee K., Walther S., Raftogianis R.B., Kuwano M., Zeng H., et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 62 (2002) 3144-3150
27. Hooijberg J.H., Broxterman H.J., Kool M., Assaraf Y.G., Peters G.J., Noordhuis P., et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59 (1999) 2532-2535
28. Wielinga P., Hooijberg J.H., Gunnarsdottir S., Kathmann I., Reid G., Zelcer N., et al. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res 65 (2005) 4425-4430
29. Zeng H., Bain L.J., Belinsky M.G., and Kruh G.D. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res 59 (1999) 5964-5967
30. Cheok M.H., Yang W., Pui C.H., Downing J.R., Cheng C., Naeve C.W., et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 34 (2003) 85-90
31. Stark M, Wichman C, Avivi I, Assaraf YG. Aberrant splicing of folylypolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia. Blood, 2009, in press.